首页> 美国卫生研究院文献>Infection and Immunity >Further Studies of the Neuraminidase Content of Inactivated Influenza Vaccines and the Neuraminidase Antibody Responses After Vaccination of Immunologically Primed and Unprimed Populations
【2h】

Further Studies of the Neuraminidase Content of Inactivated Influenza Vaccines and the Neuraminidase Antibody Responses After Vaccination of Immunologically Primed and Unprimed Populations

机译:灭活流感疫苗中神经氨酸酶含量和免疫初免人群接种疫苗后神经氨酸酶抗体反应的进一步研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Purified concentrates of influenza A/USSR/90/77(H1N1)-like, A/Texas/1/77 (H3N2)-like, and B/Hong Kong/5/72-like viruses used for preparation of investigational and licensed vaccines in 1978 to 1979 were tested for their content of neuraminidase enzyme activity. Concentrates of H1N1 virus used to prepare vaccines for clinical investigations performed in the spring of 1978 had neuraminidase activity at that time which decreased during storage to almost undetectable levels (three lots) or by 50% (one lot) by the winter of 1978. Several other lots of concentrates prepared with H1N1 virus and used for vaccine formulation had no detectable neuraminidase enzyme activity when tested in the winter of 1978, at a time when they would be administered in vaccines. The range of specific activity for different lots of concentrates was about 40-fold for A/Texas/1/77, B/Hong Kong/5/72, and A/USSR/90/77 neuraminidases. Immunogenicity of investigational vaccines prepared with tested concentrates and administered between April and July 1978 was measured in volunteers aged 13 to >50 years. Frequency of neuraminidase antibody rises to two doses of H1N1-containing vaccine was 10% in unprimed subjects aged <26 years and about 18 to 36% in older persons. The frequency of neuraminidase antibody rises to one dose of H3N2-containing vaccine varied from 0 to 32% in different groups (mean, 18%). The frequencies of neuraminidase antibody responses were always much lower than the frequencies of hemagglutinin antibody responses. These observations confirm the existence of practical difficulties in achieving uniformity of the neuraminidase content in influenza vaccines and of ensuring good immunogenicity of vaccine neuraminidase even in primed populations.
机译:用于制备研究和许可疫苗的A / USSR / 90/77(H1N1)流感样,A / Texas / 1/77(H3N2)样和B / Hong Kong / 5/72样病毒的纯化浓缩物在1978年至1979年间对它们的神经氨酸酶活性进行了测试。 1978年春季,用于制备用于临床研究的疫苗的H1N1病毒浓缩液当时具有神经氨酸酶活性,该活性在储存过程中降低到几乎不可检测的水平(三批次),到1978年冬天降低了50%(一批次)。其他许多用H1N1病毒制备并用于疫苗制剂的浓缩物,在1978年冬天进行测试时(当时将其用于疫苗),没有可检测到的神经氨酸酶活性。对于A / Texas / 1/77,B / Hong Kong / 5/72和A / USSR / 90/77神经氨酸酶,不同批次浓缩物的比活范围约为40倍。在13至> 50岁的志愿者中,测量了用受试浓缩物制备并于1978年4月至7月间施用的研究用疫苗的免疫原性。神经氨酸酶抗体升至两剂含H1N1疫苗的频率在年龄小于26岁的未初治患者中为10%,在老年人中为18%至36%。神经氨酸酶抗体的频率升高至一剂含H3N2疫苗的剂量在不同组中从0%到32%不等(平均为18%)。神经氨酸酶抗体应答的频率总是比血凝素抗体应答的频率低得多。这些观察结果证实了在实现流感疫苗中神经氨酸酶含量的均匀性和确保疫苗神经氨酸酶的良好免疫原性甚至存在致敏人群中存在实际困难。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号